{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-05-18T23:08:38.985Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   50-59   Skip unless catalyst <30d + insider cluster\n   < 50    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   < 60    Skip (no exception; small caps need a clear catalyst)\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"RARE\",\n  \"company\": \"Ultragenyx Pharmaceutical Inc.\",\n  \"investigation_summary\": \"Ultragenyx is a rare-disease biotech that has cratered 78% over five years to near the bottom of its 52-week range. The trigger — three Form 4 filings in 14 days — turns out to be RSU vest+sell activity, NOT open-market purchases (code A for grants, S for tax-withholding sales; no P-codes found). There are ZERO confirmed CEO/CFO/Director open-market buys in the lookback window. However, two high-impact catalysts exist: UX111 PDUFA Sep 19, 2026 and DTX401 PDUFA Aug 23, 2026 — both gene therapies for fatal pediatric diseases with no approved alternatives. Analyst consensus sits at $51.52 vs current $24.19 (~113% upside). The company is cash-rich ($534M liquid), guiding to $730-760M revenue in 2026 and profitability in 2027, but burns ~$800M/year in operating cash flow. The stock presents a bounded asymmetric setup around the PDUFA events: binary on approval, but heavily discounted given five-year price destruction.\",\n  \"verdict\": \"promising\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"csp\",\n    \"cc\",\n    \"strangle\"\n  ],\n  \"business_snapshot\": \"Ultragenyx Pharmaceutical is a Novato, California-based biotech commercializing four approved rare-disease therapies (Crysvita for XLH/TIO, Mepsevii for MPS VII, Dojolvi for LC-FAOD, Evkeeza for HoFH) while advancing six clinical-stage programs spanning AAV gene therapy, ASO oligonucleotides, and monoclonal antibodies. The company generates ~$730-760M in annual revenue primarily from Crysvita royalties via its Kyowa Kirin collaboration (U.S./Canada royalty territory) and direct product sales globally. Operating losses run ~$800M/year; the company targets cash-flow breakeven by 2027 as newer gene-therapy products launch. The balance sheet carries $1.2B in discounted royalty liabilities against $534M in liquid assets, reflecting sophisticated capital recycling via Royalty Pharma (RPI) and OMERS structures. The company's internal manufacturing facility for gene therapies adds regulatory complexity but also vertical integration value.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 298000,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-08-04\",\n      \"recent_eps_surprise_pattern\": \"Q1 2026 EPS missed by -18.96%; Q4 2025 missed by -10.1%; Q3 2025 catastrophically missed by -49.7%. Pattern is consistently negative, driven primarily by R&D investment and one-time royalty timing.\",\n      \"guidance_raise_in_last_90d\": false,\n      \"named_catalysts\": [\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"UX111 (rebisufligene etisparvovec) AAV9 gene therapy for Sanfilippo syndrome Type A (MPS IIIA). PDUFA Sep 19, 2026. Would be first-ever approved treatment for this fatal pediatric neurodegenerative lysosomal storage disease.\",\n          \"date_or_window\": \"PDUFA September 19, 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1515673/000119312526139084/rare-20260402.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"DTX401 (pariglasgene brecaparvovec) AAV8 gene therapy for Glycogen Storage Disease Type Ia (GSDIa). PDUFA Aug 23, 2026. Rolling BLA completed Dec 2025; FDA granted Priority Review.\",\n          \"date_or_window\": \"PDUFA August 23, 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1515673/000119312526062568/rare-20260223.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"GTX-102 (apazunersen) antisense oligonucleotide for Angelman syndrome. Phase 3 Aspire study fully enrolled with data expected H2 2026. Breakthrough Therapy + PRIME designations; 129 patients randomized.\",\n          \"date_or_window\": \"H2 2026 data readout\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1515673/000119312526057329/rare-20251231.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q1 2026 revenue $136M (missed by -15.7%); widening net loss ($185M). Company reaffirmed full-year guidance of $730-760M and maintained 2027 profitability target.\",\n          \"date_or_window\": \"May 5, 2026 earnings release\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/ultragenyx-reports-first-quarter-2026-200100547.html\"\n          ],\n          \"directional_bias\": \"ambiguous\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": 69.75,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": -6.54,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": -9.19,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"RARE has declined 78% over five years and sits ~43% below its 52-week high of $42.37, trading at $24.19 against an analyst consensus target of $51.52 (Morgan Stanley raised to $67 in April). At ~70x forward P/E the stock appears expensive on traditional metrics but this is misleading — negative FCF and heavy R&D investment distort earnings-based valuation for pre-profitability gene-therapy companies with near-term approval catalysts. The market appears to be underweighting the optionality value of two PDUFA events in 2026 (UX111 Aug/Sep, DTX401 Aug) that could double revenue if both approve.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"B\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": false,\n      \"rsi_14\": 45.4,\n      \"macd_recent_bullish_cross\": false,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 24.19,\n    \"ytd_return_pct\": -23.23,\n    \"from_52w_high_pct\": -42.9\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-02-18\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1515673/000119312526057329/rare-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY2025 revenue ~$670M; Crysvita collaboration royalty is primary U.S. revenue driver; company guided to $730-760M for 2026\",\n        \"Net loss widened significantly; accumulated deficit now $4.7B+\",\n        \"UX111 BLA resubmitted Jan 2026 after CRL in July 2025 — CMC documentation incomplete; second IRL received Feb 2026 with additional CMC requests\",\n        \"DTX401 rolling BLA completed December 2025, Priority Review granted, PDUFA Aug 23, 2026\",\n        \"GTX-102 Phase 3 Aspire fully enrolled at 129 patients; data H2 2026\",\n        \"UX143 (setrusumab/Osteogenesis Imperfecta) failed both Orbit and Cosmic Phase 3 primary endpoints Dec 2025 — negative catalyst\",\n        \"Restructuring announced Feb 2026 to reduce operating expenses toward 2027 profitability target\",\n        \"Royalty liabilities: RPI Finance Trust (Royalty Pharma) and OMERS LS23 Holdings represent $1.2B in discounted obligations\",\n        \"Company operates its own gene-therapy manufacturing facility for UX111, creating both strategic value and regulatory risk\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-06\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1515673/000119312526206960/rare-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026 total revenue $136M (vs $139M Q1 2025); net loss ($185M) vs ($151M) year prior; EPS ($1.84) miss of ~19%\",\n        \"Crysvita US royalties: non-cash portion ~$20M per quarter from RPI/OMERS structures; cash royalties separate\",\n        \"Cash and equivalents $175M + marketable securities $238M (current) + $121M (non-current) = $534M total liquid assets\",\n        \"Accrued liabilities dropped from $265M to $194M — likely Q1 payments including restructuring charges\",\n        \"Q1 R&D spend $187M (+13% YoY); SG&A $88M flat\",\n        \"Operating cash burn $197M in Q1 alone; company is burning cash at ~$800M/year run rate\",\n        \"Additional ~$30-50M in milestone payments expected to regulatory/commercial partners through 2026\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-06-18\",\n      \"2026-07-17\",\n      \"2026-08-21\",\n      \"2026-11-20\"\n    ],\n    \"iv_summary\": \"ATM IV ~89-94% at near-term expiries; elevated IV environment favorable for premium-selling strategies around PDUFA events in Aug-Sep 2026. Put skew notably heavy with $22.5 put OI of 2,820 contracts — large institutional downside hedge. Call side shows bullish positioning (27.5 call OI 122).\",\n    \"notable_skew_or_flow\": \"Put/call ratio 0.10 on near-term expiry suggests bullish directional bias in options market. Heavy put open interest at $22.5 strike (OI=2820) likely from institutional hedgers, creating a floor. August expiry straddles both PDUFA dates and could be well-suited for strangle plays if IV remains elevated.\"\n  },\n  \"competitive_landscape\": \"Ultragenyx competes with other rare-disease focused biotechs including Amgen (via Otezla), Sanofi Genzyme, and smaller gene-therapy specialists like REGENXBIO partners. Within its specific indications: UX111 has no approved competitors (Sanfilippo MPS IIIA is an ultra-rare fatal disease with zero treatments); DTX401 would be first gene therapy for GSDIa vs standard cornstarch dietary management; GTX-102 targets Angelman syndrome where no disease-modifying therapies exist. The biotech's commercial infrastructure across 60+ countries and four approved products provides distribution leverage not available to earlier-stage peers.\",\n  \"key_risks\": [\n    \"UX111 already received Incomplete Response Letter from FDA in Feb 2026 — CMC documentation incomplete; approval not guaranteed even with Sep PDUFA date\",\n    \"DTX401: similar one-time gene therapy commercial model vs existing cornstarch standard of care, reimbursement uncertainty for ~$3-5M per patient courses\",\n    \"Company has accumulated $4.7B deficit and burns ~$800M/year in operating cash flow — runway risk if multiple approvals are delayed\",\n    \"UX143 (setrusumab) failed both Phase 3 studies in OI Dec 2025 — previously a key pipeline catalyst now eliminated\",\n    \"Ongoing royalty liabilities ($1.2B face value via RPI/OMERS) represent structural capital drag; non-cash interest expense ~$21M/quarter growing\",\n    \"Gene therapy manufacturing at company-owned facility adds regulatory risk (FDA inspections are part of both BLA reviews)\",\n    \"EPS track record: 3 of last 4 quarters missed consensus; Q3 2025 miss was -49.7% — guidance credibility questioned\"\n  ],\n  \"what_the_market_might_be_missing\": \"The stock's 78% five-year decline has left it pricing in near-zero probability for UX111 approval despite (a) the FDA accepting the BLA resubmission with a September PDUFA date, (b) substantial longer-term data presented at WORLDSymposium Feb 2026 showing statistically significant cognitive benefit vs natural history in MPS IIIA patients, and (c) no approved alternatives for this universally fatal childhood disease. The market may also be underweighting the optionality from DTX401's August PDUFA — a gene therapy that could treat ~6,000 GSDIa patients globally with a potential $2-4M per-patient course value if approved and covered by payers. Additionally, Mepsevii partner renegotiation details (10-Q references 'Customer One' concentration) may not be fully priced in.\",\n  \"anti_signals_present\": [\n    \"dilution\",\n    \"going_concern\",\n    \"accounting\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"SEC 10-K FY2025 filed Feb 18 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1515673/000119312526057329/rare-20251231.htm\"\n    },\n    {\n      \"label\": \"SEC 10-Q Q1 2026 filed May 6 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1515673/000119312526206960/rare-20260331.htm\"\n    },\n    {\n      \"label\": \"FDA accepts UX111 BLA resubmission (8-K Apr 2, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1515673/000119312526139084/rare-20260402.htm\"\n    },\n    {\n      \"label\": \"DTX401 Priority Review granted (8-K Feb 23, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1515673/000119312526062568/rare-20260223.htm\"\n    },\n    {\n      \"label\": \"UX111 WORLDSymposium data release (8-K Feb 3, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1515673/000119312526034474/rare-20260203.htm\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-05-18T23:08:58.831Z",
      "raw_content": "<think>The dossier is for RARE (Ultragenyx Pharmaceutical Inc.).\nScout verdict: promising, structure hints: csp, cc, strangle.\nScoring inputs:\nSmart money: 0 insider buys, 0 CEO/CFO buys, $298k selling. Score: 0.\nOptions flow: IV ~89-94%, put OI heavy, call OI moderate. Put/call ratio 0.10. IV elevated. Score: maybe 3-4 for elevated IV/strangle setup, but no clear whale call blocks. I'll give 2.\nCatalyst: PDUFA dates in Aug/Sep 2026. Not within 90 days. No recent guidance raise. EPS misses. Score: 0.\nMispricing: Forward P/E 69.75, EV/EBITDA -6.54, FCF yield -9.19%. Not cheap. Score: 0.\nQuality: Negative FCF, accumulated deficit $4.7B, burns $800M/yr. Score: 0.\nTechnical: Above 50DMA, below 200DMA. RSI 45.4. Score: 1.\nTotal score: ~6.\nAnti-signal gates: \"dilution\", \"going_concern\", \"accounting\".\nThe dossier explicitly lists anti_signals_present: [\"dilution\", \"going_concern\", \"accounting\"].\nThe prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nGoing concern: Biotech with $4.7B deficit burning $800M/yr. Runway is ~2 years at best. High risk.\nDilution: Gene therapy biotechs often dilute.\nAccounting: Royalty liabilities, restructuring.\nGiven the score is extremely low (<10) and anti-signal gates are present, I will skip.\nReason: High cash burn, negative FCF, and active anti-signal gates (going concern, dilution, accounting) make this a high-risk biotech with no near-term catalysts or insider support.\nScore breakdown: smart_money: 0, options_flow: 2, catalyst: 0, mispricing: 0, quality: 0, technical: 1. Total: 3.\nI will output the skip JSON.\nCheck thresholds: ASYMMETRIC or CORE? Market cap isn't explicitly given, but biotechs with $4.7B deficit and $534M cash are typically small/mid-cap. I'll classify as asymmetric or core, doesn't matter since score < 50.\nI will just output the skip JSON.\nLet's verify the anti-signal rule: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will skip.\nConstruct JSON carefully.\nScore: 3\nBreakdown: smart_money: 0, options_flow: 2, catalyst: 0, mispricing: 0, quality: 0, technical: 1\nReason: Active anti-signal gates (going concern, dilution, accounting) combined with $800M annual cash burn and no near-term catalysts make this a high-risk biotech with insufficient edge for publication.\nReady.✅\nOutput matches requested format.\nNo extra text.\nProceed. \nSelf-Correction/Verification during thought:\nWait, the prompt says \"anti_signals_present\": [\"dilution\", \"going_concern\", \"accounting\"]. I should explicitly note that these gates trigger a skip. The score is low anyway.\nI will produce the skip JSON.\nAll good. \nOutput matches exactly. \nProceeds. \n{\n  \"skip\": true,\n  \"score\": 3,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 0,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 1\n  },\n  \"reason\": \"Active anti-signal gates (going concern, dilution, accounting) combined with $800M annual cash burn, negative FCF, and no near-term catalysts make this a high-risk biotech with insufficient edge for publication.\"\n}\nMatches schema. Done. \nOutput generation. \n[Done]\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 3,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 0,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 1\n  },\n  \"reason\": \"Active anti-signal gates (going concern, dilution, accounting) combined with $800M annual cash burn, negative FCF, and no near-term catalysts make this a high-risk biotech with insufficient edge for publication.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 3,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 0,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 1\n  },\n  \"reason\": \"Active anti-signal gates (going concern, dilution, accounting) combined with $800M annual cash burn, negative FCF, and no near-term catalysts make this a high-risk biotech with insufficient edge for publication.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 3,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 0,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 1\n  },\n  \"reason\": \"Active anti-signal gates (going concern, dilution, accounting) combined with $800M annual cash burn, negative FCF, and no near-term catalysts make this a high-risk biotech with insufficient edge for publication.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 19846,
  "stop_reason": "stop",
  "completed_at": "2026-05-18T23:08:58.831Z"
}